CLEARWATER, Fla.--(BUSINESS WIRE)--
Apyx Medical Corporation, formerly Bovie Medical Corporation, ( APYX ) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma ® , a patented surgical product marketed and sold under the Renuvion ® Cosmetic Technology brand in the cosmetic surgery market, today announced that Todd Hornsby has been promoted to Executive Vice President, effective January 2, 2019.
Mr. Hornsby joined Apyx Medical in August, 2014, and held the position of Vice President and General Manager of Advanced Energy prior to his promotion.
“Todd has done an excellent job leading the global sales and marketing efforts for our Advanced Energy business, specifically the commercialization of our Renuvion Cosmetic Technology in the U.S. cosmetic surgery market and in an increasing number of international markets as well,” said Charlie Goodwin, President and Chief Executive Officer. “Apyx Medical is proud to announce his promotion to Executive Vice President, and I’m confident that he will guide our team to greater success in this role.”
About Apyx Medical Corporation :
Apyx Medical Corporation (formerly Bovie Medical Corporation) is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company’s Helium Plasma Technology is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma ® in the hospital surgical market. Renuvion offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com .
Cautionary Statement on Forward-Looking Statements :
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10-K for the year ended December 31, 2017 and subsequent Form 10-Q filings. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.